The genomic landscape of recurrent ovarian high grade serous carcinoma: the BriTROC-1 study
Smith,P.,Bradley,T.,Morrill-Gavarro,L.,Goranova,T.,Ennis,D.,Mirza,H.,De Silva,D.,Piskorz,A.,Al-Khalidi,S.,Sauer,C.,Funingana,I.-G.,Reinius,M.,Giannone,G.,Lewsley,L.-A.,Stobo,J.,McQueen,J.,Bryson,G.,Eldridge,M.,Glasspool,R.,Gourley,C.,Kennedy,R.,Hall,G.,Edmondson,R.,Clamp,A.,Sundar,S.,Walter,A.,Hall,M.,Fotopoulou,C.,Lockley,M.,Brockbank,E.,Mones,A.,Gabra,H.,Macintyre,G.,Markowetz,F.,Brenton,J. D.,McNeish,I. A.
DOI: https://doi.org/10.1101/2022.10.21.22280992
2022-10-26
MedRxiv
Abstract:Background Ovarian high grade serous carcinoma (HGSC) initially responds well to platinum-based chemotherapy, but recurrence is frequent. The drivers of recurrence and resistance remain unclear. We established BriTROC-1 to investigate the acquisition of resistance by collecting tumour biopsies from women with relapsed HGSC. Patients and methods Eligible patients had recurrent ovarian HGSC that had relapsed following at least one line of platinum-based chemotherapy. Patients underwent biopsy or secondary debulking surgery, with tumour samples fixed in methanol. All treatment after study entry was at the discretion of the treating oncologist. Normal and tumour DNA samples underwent tagged-amplicon panel sequencing. Tumour DNA underwent shallow whole genome sequencing (sWGS). Tissue microarrays (TMA), created from diagnosis samples, were stained for CD3, CD8, CD20 and FoxP3. Results 276 patients were recruited (209 platinum-sensitive, 67 platinum-resistant). Panel sequencing showed close concordance between diagnosis and relapse, with only 4 discordant cases, and no revertant mutations in BRCA1 or BRCA2 identified in relapse samples. There was also very strong concordance in copy number (CN) between diagnosis and relapse, with no significant difference in purity, ploidy or focal somatic CN alterations at relapse, even when stratified by platinum sensitivity or prior chemotherapy lines. Small increases in CN signature 3 and 7 exposure were observed between diagnosis and relapse across the whole cohort. However, these differences disappeared when analysing matched sample pairs. Diagnosis samples from patients with primary platinum resistance had increased rates of CCNE1 and KRAS amplification and CN signature 6 exposure. Finally, we found strong correlations between CN signatures and immune cell infiltration. Conclusions The HGSC genome is remarkably stable between diagnosis and relapse and does not explain acquired chemotherapy resistance. However, we have identified new genomic events at diagnosis, including KRAS amplification and CN signature 6 exposure, that are associated with primary platinum resistance.